Related Experiment Videos
Cardiac effects of chronic inflammation in dialysis patients
Antonio Santoro1, Elena Mancini
1Malpighi Nephrology and Dialysis Division, Policlinico S. Orsola-Malpighi, Bologna, Italy.
Insights
Chronic inflammation in uremia significantly contributes to cardiovascular disease, accelerating atherosclerosis and myocardial dysfunction, increasing risks of heart attack and death. Investigating inflammation markers and cytokines is crucial for better diagnosis and treatment.
Area of Science:
- Nephrology
- Cardiology
- Pathology
Background:
- Cardiovascular pathology is a leading cause of mortality in uremia.
- Chronic inflammation, marked by elevated C-reactive protein, interleukin-6, and tumor necrosis factor-alpha, is linked to vascular damage in general and dialysis populations.
- The vascular wall is a primary target of inflammatory processes.
Purpose of the Study:
- To explore the role of chronic inflammation and cytokines in the development of cardiovascular pathology in uremic patients.
- To highlight the impact of inflammation on atherosclerosis, plaque instability, and myocardial dysfunction.
- To emphasize the need for improved diagnostic markers and therapeutic strategies for cardiovascular disease in uremia.
Main Methods:
- Review of existing evidence linking inflammation markers (C-reactive protein, IL-6, TNF-alpha) to cardiovascular pathology in uremia.
- Analysis of the mechanisms by which cytokines affect vascular walls and myocardial function.
- Discussion of diagnostic and therapeutic implications.
Main Results:
- Increased pro-inflammatory cytokines in uremia promote atherosclerosis, plaque rupture, and myocardial dysfunction.
- Inflammation is directly associated with vascular pathology and contributes to clinical syndromes.
- Combined effects of atherosclerosis and myocardial dysfunction elevate risks of myocardial infarction and death.
Conclusions:
- Cardiovascular disease in uremia is strongly influenced by chronic inflammation and cytokine profiles.
- Biochemical inflammation markers and circulating cytokine levels are vital for assessing cardiovascular risk.
- Further research into novel markers and therapeutic interventions is warranted to mitigate cardiovascular mortality in uremic patients.
Abstract:
Cardiovascular pathology is the major cause of death in uraemia. There is evidence that a chronic inflammation with activation of C-reactive protein, interleukin-6, tumour necrosis factor-alpha and other cytokines is associated with vascular pathology, both in the general population and in dialysis patients. The cardiovascular system, and particularly the vascular wall, is the main target of the inflammatory process. Inflammation of the coronary arteries could be involved in the development of atherosclerosis and its related clinical syndromes. In the uraemic state, an increased production of pro-inflammatory cytokines may trigger the onset and progression of atherosclerosis and favour the subsequent complications, such as plaque fissuration and rupture. However, inflammatory cytokines also have a depressant action on the myocardium, thus inducing myocardial dysfunction. Together, these conditions may ultimately enhance the risk of myocardial infarction and death. From this standpoint, cardiovascular disease should also be investigated with the traditional biochemical inflammation markers and the evaluation of the circulating cytokine level, although new reliable markers could provide further diagnostic help. New therapeutic approaches should also be considered.